Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Teva Pharmaceutical Industries Earnings Call: Key Takeaways

Teva is successfully transitioning to a biopharma model, raising 2026 revenue guidance to $16.7B-$17B and achieving investment-grade status while scaling innovative products like Austedo and Uzedy.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthInnovative up 33%; US Generics down 3%; EU Generics up 7%.
Mgmt ConfidenceHigh confidence in achieving $2.5B Austedo target one year early.
Demand VisibilityAustedo US TRX up 18%; Uzedy TRX up 62% year-over-year.
Margin TrendsNon-GAAP gross margin 58.7%, up 245 bps; operating margin 31.7%.
Op. LeverageStructural cost savings and productivity improvements driving 30% operating margin target.
Pricing PowerAustedo pricing environment noted as challenging ahead of 2027 IRA implementation.
Vol vs PriceGrowth driven by innovative product mix and volume; generics revenue declined.
Segment GrowthInnovative portfolio accelerating; Biosimilars on track for $800M by 2026.
New ClientsStrengthened partnership with Samsung for two FDA-approved TNF alpha biosimilars.
Capex & DebtRepaid $1.8B debt in October; net debt to EBITDA target 2x.
RegulatoryFDA Fast Track for KTR-15; discontinued Emersonalmen study due to futility.
CommentaryTransitioning from a generic-driven company to a high-margin biopharma powerhouse.
New LaunchesLaunched Welltruza for schizophrenia; acquired BXCL-501 for acute agitation.

Growth

Innovative portfolio up 33%; Austedo grew 21% to $751M; Uzedy up 96% to $85M.

Outlook

Targeting $2.5B-$2.65B Austedo sales in 2026 and 30% operating margin by 2027.

Risks

Management pivoted on specific 2027 Austedo IRA impacts and Symphony biosimilar litigation timelines.

Source

The company's earnings call, NYSE: TEVA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Teva Pharmaceutical Industries Ltd: key numbers

Share price
$42.57Close, Nov 16
Market cap
$49.7B
Shares outstanding
1.17BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Teva Pharmaceutical Industries Ltd

All →
4:16 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries EVP, Europe Commercial Richard Daniell Sells $1.93M of Stock

Richard Daniell, EVP, Europe Commercial, sold 45,003 shares of Teva Pharmaceutical Industries Ltd at $42.80 to $42.91 a share (average $42.86) in 2 transactions, worth $1.93M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 55,755 (-26.4%).

Value
$1.93M
Shares
45,003
Average price
$42.86
Role
EVP, Europe Commercial
Holding change
-26.4%
Trade date
Nov 9, 2026 to Nov 11, 2026
4:14 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries President and CEO Richard D. Francis Sells $10.6M of Stock

Richard D. Francis, President and CEO, sold 250,000 shares of Teva Pharmaceutical Industries Ltd at $42.24 a share, worth $10.6M in total on Nov 10, 2026. Shares held after the trade: 927,529 (-21.2%).

Value
$10.6M
Shares
250,000
Price
$42.24
Role
President and CEO
Holding change
-21.2%
Trade date
Nov 10, 2026
4:12 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.97M of Stock

Mark Sabag, See "Remarks", sold 44,710 shares of Teva Pharmaceutical Industries Ltd at $44.14 a share, worth $1.97M in total on Nov 12, 2026. Shares held after the trade: 80,760 (-35.6%).

Value
$1.97M
Shares
44,710
Price
$44.14
Role
See "Remarks"
Holding change
-35.6%
Trade date
Nov 12, 2026
4:11 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries CAO Amir Weiss Sells $744K of Stock

Amir Weiss, CAO, sold 17,289 shares of Teva Pharmaceutical Industries Ltd at $43.03 to $43.15 a share (average $43.04) in 3 transactions, worth $744K in total on Nov 9, 2026. Shares held after the trade: 3,537 (-72.9%).

Value
$744K
Shares
17,289
Average price
$43.04
Role
CAO
Holding change
-72.9%
Trade date
Nov 9, 2026
4:04 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.93M of Stock

Mark Sabag, See "Remarks", sold 46,000 shares of Teva Pharmaceutical Industries Ltd at $41.93 a share, worth $1.93M in total on Nov 5, 2026. Shares held after the trade: 80,760 (-36.3%).

Value
$1.93M
Shares
46,000
Price
$41.93
Role
See "Remarks"
Holding change
-36.3%
Trade date
Nov 5, 2026
4:02 PM ET Form 4
Insider Selling

Teva Pharmaceutical Industries Interim Cheif Legal Officer Dov Bergwerk Sells $1.1M of Stock

Dov Bergwerk, Interim Cheif Legal Officer, sold 26,260 shares of Teva Pharmaceutical Industries Ltd at $41.72 a share, worth $1.1M in total on Nov 4, 2026. Shares held after the trade: 11,943 (-42.3%).

Value
$1.1M
Shares
26,260
Average price
$41.72
Role
Interim Cheif Legal Officer
Holding change
-42.3%
Trade date
Nov 4, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.